Investigating a Personalized Approach to Anti-Platelet Therapy

Starting soon · Phase 4

Conditions studied: High Risk Bleeding

In brief

RAPID PREVENT aims to identify if a personalized (targeted) anti-platelet strategy will reduce bleeding events when compared to the current standard anti-platelet therapy.

Key facts

Study ID

NCT07602257

Run by

Ottawa Heart Institute Research Corporation

People needed

1760

Starts

2026-06-01

Expected to finish

2029-12-28

Last updated by the study team

2026-05-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >18 years old
• Receiving PCI with stenting

You may not qualify if…

• Inability to take ticagrelor
• Inability to take clopidogrel
• Not expected to survive >48hours
• Not able to complete a buccal swab

Where it is running

• University of Ottawa Heart Institute — Ottawa, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.